Fruquintinib, cadonilimab, and temozolomide for advanced melanoma
Part of Cancer, Skin clinical trials.
This study tests a combination of three drugs for people with advanced melanoma that has not responded to previous treatment. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage IV melanoma (cancer that has spread).
- Your melanoma has not improved after at least one prior treatment.
- You have not had chemotherapy, immunotherapy, or targeted therapy within the last 4 weeks.
- You are generally in good health (able to care for yourself, up and about).
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (Fluzoparib, Camrelizumab, and Temozolomide) for people with advanced melanoma that has spread or cannot be removed by surgery. It is for those who have a specific genetic change (HR or SF3B1 mutation) and have not been treated with a PARP inhibitor before.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial tests two new drugs (cadonilimab and anlotinib) for people with melanoma that has spread or grown after their first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
Hear when a new Malignant Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.